Drug therapy in the management of type 1 autoimmune hepatitis

Drugs

Volumn 57, Issue 1, 1999, Pages 49-68

  Czaja, Albert J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; IMMUNOGLOBULIN G; PREDNISONE; TACROLIMUS;

ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; DRUG WITHDRAWAL; IMMUNOGLOBULIN BLOOD LEVEL; LIVER HISTOLOGY; LIVER NECROSIS; LIVER TRANSPLANTATION; MAINTENANCE THERAPY; PATIENT MONITORING; RECURRENT DISEASE; RELAPSE; REMISSION; REVIEW; SIDE EFFECT; SYMPTOM;

AZATHIOPRINE; DISEASE SUSCEPTIBILITY; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PREDNISONE; TREATMENT OUTCOME;

EID: 0032892468     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957010-00005     Document Type: Review

References (152)

1. 1. Czaja AJ. Autoimmune hepatitis: evolving concepts and treatment strategies. Dig Dis Sci 1995 Feb; 40: 435-56
2. 2. Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol 1994; 21: 866-71
3. 3. Johnson PJ, McFarlane IG, Alvarez F, et al. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993 Oct; 18: 998-1005
4. 4. Czaja AJ, Carpenter HA. Validation of a scoring system for the diagnosis of autoimmune hepatitis. Dig Dis Sci 1996 Feb; 41: 305-14
5. 5. Czaja AJ, Manns MP. The validity and importance of subtypes of autoimmune hepatitis: a point of view. Am J Gastroenterol 1995 Aug; 90: 1206-11
6. 6. Homberg J-C, Abuaf N, Bernard O, et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of 'autoimmune' hepatitis. Hepatology 1987 Jun; 7: 1333-9
7. 7. Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 1992 Oct; 103: 1290-5
8. 8. Manns MP, Griffin KJ, Sullivan KF, et al. LKM-I autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 1991 Oct; 88: 1370-8
9. 9. Manns M, Gerken G, Kyriatsoulis A, et al. Characterization of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987 Feb; 1: 292-4
10. 10. Stechemesser E, Klein R, Berg PA. Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis. Hepatology 1993 Jul; 18: 1-9
11. 11. Czaja AJ, Carpenter HA, Manns MP. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology 1993 Nov; 105: 1522-8
12. 12. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971 Apr; 40: 159-85
13. 13. Soloway RD, Summerskill WHJ, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972 Nov; 63: 820-33
14. 14. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973 Apr; 1: 735-7
15. 15. Maggiore G, Bernard O, Homberg J-C, et al. Liver disease associated with anti-liver-kidney microsome antibody in children. J Pediatr 1986; 108: 399-404
16. 16. Czaja AJ. Autoantibodies. Baillieres Clin Gastroenterol 1995 Dec; 9: 723-44
17. 17. Cochrane AMG, Moussouros A, Thomson AD, et al. Antibody-dependent cell-mediated (K cell) cytotoxicity against isolated hepatocytes in chronic active hepatitis. Lancet 1976; 1: 441-4
18. 18. Vento S, Noun-Aria KT, Eddleslton ALWF. Immune mechanisms in autoimmune chronic active hepatitis. Scand J Gastroenterol 1985; 20 Suppl. 114: 91-103
19. 19. McFarlane IG, McFarlane BM, Major GN, et al. Identification of the hepatic asialo-glycoprotein receptor (hepatic lectin) as a component of liver specific membrane lipoprotein (LSP). Clin Exp Immunol 1984; 55: 347-54
20. 20. Poralla T, Treichel U, Lohr H, et al. The asialoglycoprotein receptor as target structure in autoimmune liver diseases. Semin Liver Dis 1991; 11: 215-22
21. 21. Loeper J, Descatoire V, Maurice M, et al. Cytochromes P-450 in human hepatocyte plasma membrane: recognition by several autoantibodies. Gastroenterology 1993; 104: 203-16
22. 22. Czaja AJ. Autoimmune hepatitis and viral infection. Gastroenterol Clin North Am 1994 Sep; 23: 547-66
23. 23. Vento S, Garofano T, Di Perri G, et al. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet 1991; 337: 1183-7
24. 24. Huppertz H-K, Treichel U, Gassel AM, et al. Autoimmune hepatitis following hepatitis A viras infection. J Hepatol 1995; 23: 204-8
25. 25. Laskus T, Slusarczyk J. Autoimmune chronic active hepatitis developing after acute type B hepatitis. Dig Dis Sci 1989; 34: 1294-7
26. 26. Magrin S, Craxi A, Fiorentino G, et al. Is autoimmune chronic active hepatitis a HCV-related disease? J Hepatol 1991; 13: 56-60
27. 27. Magrin S, Craxi A, Fabiano C, et al. Hepatitis C virus replication in 'autoimmune' chronic hepatitis. J Hepatol 1991; 13: 364-7
28. 28. Ramadori G, Lohr H, Rossol S, et al. Human immunodeficiency virus infection mimics autoimmune hepatitis - a case report. Klin Wochenschr 1988; 66: 1040
29. 29. Robertson DAF, Zhang SL, Guy EC, et al. Persistent measles virus genome in autoimmune chronic active hepatitis. Lancet 1987; 11: 9-11
30. 30. Kalland K-H, Endresen C, Haukenes G, et al. Measles-specific nucleotide sequences and autoimmune chronic active hepatitis. Lancet 1989; 1: 1390-1
31. 31. Czaja AJ. Overlap of chronic viral hepatitis and autoimmune hepatitis. In: Willson RA, editor. Viral hepatitis: diagnosis, treatment, prevention. New York: Marcel Dekker, 1997: 371-99
32. 32. Reynolds TB, Peters RL, Yamada S. Chronic active and lupoid hepatitis caused by a laxative, oxyphenisatin. N Engl J Med 1971; 285: 813-20
33. 33. Maddrey WC, Boitnott JK. Severe hepatitis from methyldopa. Gastroenterology 1975; 68: 351-60
34. 34. Rodman JS, Deutsch DJ, Gutman SI. Methyldopa hepatitis: a report of six cases and review of the literature. Am J Med 1976; 60: 941-8
35. 35. Sharp JR, Ishak KG, Zimmerman HJ. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med 1980; 92: 14-9
36. 36. Gough A, Chapman S, Wagstaff K, et al. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ 1996; 312: 169-72
37. 37. Crosson J, Stillman MT. Minocycline-related lupus erythematosus with associated liver disease. J Am Acad Dermatol 1997 May; 36: 867-8
38. 38. Herzog D, Hajoui O, Russo P, et al. Study of immune reactivity of minocycline-induced chronic active hepatitis. Dig Dis Sci 1997; 42: 1100-3
39. 39. Helfgott SM, Sandherg-Cook J, Zakim D, et al. Diclofenacassociated hepatotoxicity. JAMA 1990; 264: 2660-2
40. 40. Scully LJ, Clarke D, Barr RJ. Diclofenac induced hepatitis: 3 cases with features of autoimmune chronic active hepatitis. Dig Dis Sci 1993; 38: 744-51
41. 41. Sterling MJ, Kane M, Grace ND. Pemoline-induced autoimmune hepatitis. Am J Gastroenterol 1996; 91: 2233-4
42. 42. Fedotin MS, Lefer LG. Liver disease caused by propylthiouracil. Arch Intern Med 1975; 135: 319-21
43. 43. Ogburn RM, Myers RL, Burdick GE. Hepatitis associated with dantrolene sodium. Ann Intern Med 1976 Jan; 84: 53-4
44. 44. Utili R, Boitnott J, Zimmerman HJ. Dantrolene associated hepatic injury. Gastroenterology 1977; 72: 610-6
45. 45. Tonder M, Norday A, Elgjo K. Sulfonamide-induced chronic liver disease. Scand J Gastroenterol 1974; 9: 93-6
46. 46. Black M, Mitchell JR, Zimmerman HJ, et al. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975 Aug; 69: 289-302
47. 47. Kamiyama T, Nouchi T, Kojima S, et al. Autoimmune hepatitis triggered by administration of an herbal medicine. Am J Gastroenterol 1997; 92: 703-4
48. 48. Maddrey WC, Boitnott JK. Drug-induced chronic liver disease. Gastroenterology 1977 Jun; 72: 1348-53
49. 49. Seeff LB. Drug-induced chronic liver disease, with emphasis on chronic active hepatitis. Semin Liver Dis 1981; 1: 104-15
50. 50. Donaldson PT, Doherty DG, Hayllar KM, et al. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 1991; 13: 701-6
51. 51. Czaja AJ, Carpenter HA, Santrach PJ, et al. Genetic predispositions for the immunological features of chronic active hepatitis. Hepatology 1993 Oct; 18: 816-22
52. 52. Sanchez-Urdazpal L, Czaja AJ, van Hock B, et al. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology 1992 Feb; 15: 215-21
53. 53. Czaja AJ, Carpenter HA, Santrach PJ, et al. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 1993 Nov; 105: 1502-7
54. 54. Strettell MDJ, Donaldson PT, Thomson LJ, et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 1997 Jun; 112: 2028-35
55. 55. Czaja AJ, Strettell MDJ, Thomson LJ, et al. Associtions between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 1997 Feb; 25: 317-23
56. 56. Czaja AJ, Kruger M, Santrach PJ, et al. Generic distinctions between types 1 and 2 autoimmune hepatitis. Am J Gastro enterol 1997 Dec; 92: 2197-200
57. 57. Currie MS. Immunosenescence. Comprehensive Ther 1992 Nov; 18 (11): 26-34
58. 58. Schwab R, Russo C, Weksler ME. Altered major histocompatibility complex-restricted antigen recognition by T cells from elderly humans. Eur J Immunol 1992; 22: 2989-93
59. 59. Talor E, Rose NR. Hypothesis: the aging paradox and autoimmune disease. Autoimmunity 1991; 8: 245-9
60. 60. Villanueva JL, Solana R, Alonso MC. et al. Changes in the expression of HLA class II antigens on peripheral blood monocytes from aged humans. Dis Markers 1990 Mar-Apr: 8 (2): 85-91
61. 61. Murasko DM, Goonewardene IM. T cell function in aging: mechanisms of decline. Ann Rev Gerontol Geriatr 1990; 10: 71-96
62. 62. Orson FM, Saadeh C, Lewis DE, et al. Inlerleukin 2 receptor expression by T cells in human aging. Cell Immunol 1989 Dec; 124 (2): 278-91
63. 63. Nagel JE, Chopra RK, Powers DC, et al. Effects of age on the human high affinity interleukin 2 receptor of phytohaemagglutinin stimulated peripheral blood lymphocytes. Clin Exp Immunol 1989 Feb; 75 (2): 286-91
64. 64. Candore C, Di Lorenzo G, Caruso C, et al. The effect of age on mitogen responsive T cell precursors in human beings is completely restored by interleukin-2. Mech Ageing Dev 1992 May; 63 (3): 297-307
65. 65. Paganelli R, Quinti I, Fagiolo U, et al. Changes in circulating B cells and immunoglobulin classes and subclasses in a healthy aged population. Clin Exp Immunol 1992 Nov; 90 (2): 351-4
66. 66. Scully LJ, Toze C, Sengar DPS, et al. Early-onset autoimmune hepatitis is associated with a C4A gene deletion. Gastroenterology 1993 May; 104: 1478-84
67. 67. Rowley MJ, Mackay IR. Measurement of antibody-producing capacity in man: I. The normal response to flagellan from Salmonella adelaide. Clin Exp Immunol 1969; 5: 407-18
68. 68. Hooper B, Whittingham S, Mathews JD, et al. Autoimmunity in a rural community. Clin Exp Immunol 1972; 12: 79-87
69. 69. Czaja AJ, Davis GL, Ludwig J, et al. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 1983 Sep. 85: 713-7
70. 70. Czaja AJ. Natural history, clinical features, and treatment of autoimmune hepatitis. Semin Liver Dis 1984; 4 (1): 1-12
71. 71. Mackay IR, Whittingham S, Tait B. Genetic control of immune responsiveness in man. Vox Sang 1977; 32: 10-19
72. 72. Chiovato L, Lapi P, Fiore E, et al. Thyroid autoimmunisty and female gender. J Endocrinol Invest 1993; 16: 384-91
73. 73. Blomberg G, Geckeler WR, Weigert M. Genetics of the antibody response to dextran in mice. Science 1972; 177: 178-80
74. 74. Talal N, Roubinian JR. Sex hormones and autoimmunity. In: Rose NR, Bigazzi PE, Warner NL, editors. Genetic control of autoimmune disease. New York: Elsevier-North Holland, 1978: 163-74
75. 75. Van Griensven M, Bergijk EC, Baelde JJ, et al. Differential effects of sex hormones on autoantibody production and proteinuria in chronic graft-versus-host disease-induced experimental lupus nephritis. Clin Exp Immunol 1997; 107: 254-60
76. 76. Czaja AJ, Carpenter HA, Santrach PJ, et al. Genetic predispositions for immunological features in chronic liver diseases other than autoimmune hepatitis. J Hepatol 1996; 24: 52-9
77. 77. Czaja AJ, Santos RM, Porto A, et al. The immune phenotype of chronic liver disease. Dig Dis Sci 1998 Sep: 43: 2149-55
78. 78. Geall MG, Schoenfield LJ, Summerskill WHJ. Classification and treatment of chronic active liver disease. Gastroenterology 1972 Dec; 63: 458-65
79. 79. Schalm SW, Korman MG, Summerskill WHJ, et al. Severe chronic active liver disease: prognostic significance of initial morphologic patterns. Am J Dig Dis 1977 Nov; 22: 973-80
80. 80. DeGroote J, Fevery J, Lepoutre L. Long-term follow-up of chronic active hepatitis of moderate severity. Gut 1978; 19: 510-3
81. 81. Fevery J, Desmet VJ, DeGroote J. Long-term follow-up and management of asymptomatic chronic active hepatitis. In: Cohen S, Soloway RD, editors. Chronic active liver disease. New York: Churchill Livingstone, 1983: 51-64
82. 82. Kemeny MJ, O'Hanlon G, Gregory PB. Asymptomatic chronic active hepatitis - prognosis and treatment [abstract]. Gastroenterology 1984; 86: 1325
83. 83. Cooksley WGE, Bradbear RA, Robinson W, et al. The prognosis of chronic active hepatitis without cirrhosis in relation to bridging necrosis. Hepatology 1986; 6: 345-8
84. 84. Roberts SK, Therneau T, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996 Mar; 110: 848-57
85. 85. Summerskill WHJ, Korman MG, Ammon HV, et al. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 1975; 16: 876-83
86. 86. Czaja AJ. Diagnosis and therapy of autoimmune liver disease. Med Clin North Am 1996 Sep; 80: 973-94
87. 87. Schalm SW, Summerskill WHJ, Go VLW. Prednisone for chronic active liver disease: pharmacokinetics, including conversion to prednisolone. Gastroenterology 1977 May; 72: 910-3
88. 88. Uribe M, Schalm SW, Summerskill WHJ, et al. Oral prednisone for chronic liver disease: dose responses and bioavailability studies. Gut 1978; 19: 1131-5
89. 89. Uribe M, Summerskill WHJ, Go VLW. Comparative serum prednisone and prednisolone concentrations following administration to patients with chronic active liver disease. Clin Pharmacokinet 1982; 7: 452-9
90. 90. Fauci AS, Dale DC. The effect of in vivo hydrocortisone on subpopulations of human lymphocytes. J Clin Invest 1974; 53: 240-6
91. 91. Yu DTY, Clements PJ, Paulus HE, et al. Human lymphocyte subpopulations: effect of corticosteroids. J Clin Invest 1974; 53: 565-71
92. 92. Frazer IH, Mackay IR. T lymphocyte supopulations defined by two sets of monoclonal antibodies in chronic active hepatitis and systemic lupus erythematosus. Clin Exp Immunol 1982; 128: 95-9
93. 93. Thomas HC, Brown D, Labrooy J, et al. T cell subsets in autoimmune and HBV-induced chronic liver disease, HBs antigen carriers with normal histology and primary biliary cirrhosis: a review of the abnormalities and the effects of treatment. J Clin Immunol 1982; 2 Suppl: 57S-60S
94. 94. Brown TE, Ahmed A, Filo RS, et al. The immunosuppressive mechanism of azathioprine: I. In vitro effect on lymphocyte function in the baboon. Transplantation 1976 Jan; 21: 27-35
95. 95. Colucci G, Colombo M, Del Ninno E, et al. In situ characterization by monoclonal antibodies of the mononuclear cell infiltrate in chronic active hepatitis. Gastroenterology 1983; 85: 1138-45
96. 96. Montano L, Aranguibel F, Boffill M, et al. An analysis of the composition of the inflammatory infiltrate in autoimmune and hepatitis B virus-induced chronic liver disease. Hepatology 1983; 3: 292-6
97. 97. Si L, Whiteside TL, Schade RR, et al. Studies of lymphocyte subpopulations in the liver tissue and blood of patients with chronic active hepatitis (CAH). J Clin Immunol 1983; 3: 408-19
98. 98. Czaja AJ, Wang KK, Shiels MT, et al. Oral pulse prednisone therapy after relapse of severe autoimmune chronic active hepatitis: a prospective randomized treatment trial evaluating clinical, biochemical, and lymphocyte subset responses. J Hepatol 1993; 17: 180-6
99. 99. Chase WF, Winn RE, Mayes GR. Oral pulse prednisone therapy in the treatment of HBsAg negative chronic active hepatitis. Gastroenterology 1982; 83: 1292-6
100. 100. Noari-Aria KJ, Hegarty JE, Alexander GJM, et al. Effect of corticosteroids on suppressor-cell activity in 'autoimmune' and viral chronic active hepatitis. N Engl J Med 1982; 307: 1301-4
101. 101. Stellon AJ, Davies A, Compston J, et al. Bone loss in autoimmune chronic active hepatitis on maintenance corticosteroid therapy. Gastroenterology 1985 Nov; 89: 1078-83
102. 102. Wang KK, Czaja AJ. Prognosis of corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis in postmenopausal women: a retrospective analysis. Gastroenterology 1989 Nov; 97: 1288-93
103. 103. Wolfhagen FHJ, van Buuren HR, den Ouden JW, et al. Cyclical etidronate in the prevention of hone loss in corticosteroid-treated primary biliary cirrhosis: a prospective, controlled pilot study. J Hepatol 1997; 26: 325-30
104. 104. Guanabens N, Pares A, Monegal A, et al. Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years. Gastroenterology 1997 Jul; 113: 219-24
105. 105. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on hone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437-43
106. 106. Czaja AJ. Diagnosis, prognosis, and treatment of classical autoimmune chronic active hepatitis. In: Krawitt EL, Wiesner RH, editors. Autoimmune liver disease. New York: Raven Press, 1991: 143-66
107. 107. Czaja AJ, Davis GL, Ludwig J, et al. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 1984; 4 (4): 622-7
108. 108. DePinho RA, Goldherg CS, Lefkowitch JH. Azathioprine and the liver: evidence favoring idiosyncratic, mixed cholestatichepatocellular injury in humans. Gastroenterology 1984; 86: 162-5
109. 109. Read AE, Wiesner RH, LaBrecque DR, et al. Hepatic venoocclusive disease associated with renal transplantation and azathioprine therapy. Ann Intern Med 1986 May; 104: 651-5
110. 110. Katzka DA, Saul SH, Jorkasky D, et al. Azathioprine and hepatic venocclusive disease in renal transplant patients. Gastroenterology 1986 Feb; 90: 448-54
111. 111. Rosenkrantz JG, Githens JH, Cox SM, et al. Azathioprine (Imuran) and pregnancy. Am J Obstet Gynecol 1967 Feb; 97: 387-94
112. 112. Wang KK, Czaja AJ, Beaver SJ, et al. Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Hepatology 1989; 10 (1): 39-43
113. 113. Penn I. Tumor incidence in allograft recipients. Transplant Proc 1979; 11: 1047-51
114. 114. Lewis GP, Jusko WJ, Burke CW, et al. Prednisone side-effects and serum protein levels: a collaborative study. Lancet 1971 Oct; 11: 778-81
115. 115. Uribe M, Go VLW, Kluge D. Prednisone for chronic active hepatitis: pharmacokinetics and serum binding in patients with chronic active hepatitis and steroid major side effects. J Clin Gastroenterol 1984 Aug; 6: 331-5
116. 116. Czaja AJ, Wolf AM, Baggenstoss AH. Laboratory assessment of severe chronic active liver disease (CALD): correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 1981 Apr; 80: 687-92
117. 117. Czaja AJ, Ammon HV, Summerskill WHJ. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. Gastroenterology 1980 Mar; 78: 518-23
118. 118. Czaja AJ, Ludwig J, Baggenstoss AH, et al. Corticosteroid-treated chronic active hepatitis in remission. Uncertain prognosis of chronic persistent hepatitis. N Engl J Med 1981 Jan; 304: 5-9
119. 119. Czaja AJ, Beaver SJ, Shiels MT. Sustained remission following corticosteroid therapy of severe HBsAg-negative chronic active hepatitis. Gastroenterology 1987 Jan; 92 (1): 215-9
120. 120. Czaja AJ, Magrin S, Fabiano C, et al. Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis. Dig Dis Sci 1995 Jan; 40: 33-40
121. 121. Czaja AJ. The variant forms of autoimmune hepatitis. Ann Intern Med 1996 Oct. 125: 588-98
122. 122. Hegarty JE, Nouri-Aria KT, Portmann B, et al. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 1983; 3: 685-9
123. 123. Czaja AJ. Low dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology 1990 Jun; 11: 1044-9
124. 124. Stellon AJ, Keating JJ, Johnson PJ, et al. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology 1988; 8: 781-4
125. 125. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995 Oct; 333: 958-63
126. 126. Davis GL, Czaja AJ, Ludwig J. Development and prognosis of histologic cirrhosis in corticosteroid-treated HBsAg-negative chronic active hepatitis. Gastroenterology 1984 Dec; 87: 1222-7
127. 127. Runyon BA. Exquisite sensitivity to small decrements in corticosteroid dose in autoimmune chronic active hepatitis. J Clin Gastroenterol 1987 Oct; 9 (5): 541-2
128. 128. Schalm SW, Ammon HV, Summerskill WHJ. Failure of customary treatment in chronic active liver disease: causes and management. Ann Clin Res 1976; 8: 221-7
129. 129. Ben Ari Z, Mehta A, Lennard L, et al. Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis. J Hepatol 1995; 23: 351-4
130. 130. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997 Apr; 126: 608-14
131. 131. Sempoux C, Horsmans Y, Lerut J, et al. Acute lobular hepatitis as the first manifestation of recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver 1997; 17: 311-5
132. 132. Neuberger J, Portmann B, Calne R, et al. Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting. Transplantation 1984; 37: 363-5
133. 133. Wright HL, Bou-Abboud CF, Hassanein T. et al. Disease recurrence and rejection following liver transplantation for autoimmune chronic active liver disease. Transplantation 1992; 53: 136-9
134. 134. Czaja AJ. Chronic active hepatitis: the challenge for a new nomenclature. Ann Intern Med 1993 Sept; 119 (6): 510-7
135. 135. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998 Aug; 28: 360-5
136. 136. Czaja AJ, Carpenter HA, Santrach PJ, et al. The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology 1993 Jun; 104 (6): 1755-61
137. 137. Hegarty JE, Nouri-Aria KT, Eddleston ALWF, et al. Controlled trial of a thymic hormone extract (thymostimulin) in 'autoimmune' chronic active hepatitis. Gut 1984 Mar; 25: 279-83
138. 138. Jenkins PJ, Portmann BP, Eddleston ALWF, et al. Use of polyunsaturated phosphatidyl choline in HBsAg negative chronic active hepatitis: results of prospective double-blind controlled trial. Liver 1982; 2: 77-81
139. 139. Van Thiel DH, Wright H, Carroll P, et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995 May; 90: 771-6
140. 140. Thomson AW. FK-506: profile of an important new immunosuppressant. Transplant Rev 1990; 4: 1-13
141. 141. Frizell E, Abraham A, Doolittle M, et al. FK506 enhances fibrogenesis in in vitro and in vivo models of liver fibrosis in rats. Gastroenterology 1994 Aug; 107: 492-8
142. 142. Clissold SP, Heel RC. Budesonide: a preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs 1984; 28: 485-518
143. 143. Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994; 8: 585-90
144. 144. Bruno A, Cavallo-Perin P, et al. Deflazacort vs prednisone: effect on blood glucose control in insulin-treated diabetics. Arch Intern Med 1987 Apr; 147: 679-80
145. 145. Rebollo J, Pinar A, Utrilla MC, et al. Deflazacort in the maintenance therapy of autoimmune hepatitis [abstract]. Hepatology 1996 Oct; 24: 236A
146. 146. Mistilis SP, Vickers CR, Darroch MH, et al. Cyclosporin, a new treatment for autoimmune chronic active hepatitis. Med J Aust 1985 Nov; 143: 463-5
147. 147. Hyams JS, Ballow M, Leichtner AM. Cyclosporine treatment of autoimmune chronic active hepatitis. Gastroenterology 1987 Oct; 93: 890-3
148. 148. Minuk GY. Cyclosporin A in nontransplant-related liver disease. Am J Gastroenterol 1989 Nov; 84: 1345-50
149. 149. Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type 1 autoimmune chronic active hepatitis. J Hepatol 1994 Dec; 21: 1040-7
150. 150. Jackson LD, Song E. Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut 1995 Mar; 36: 459-61
151. 151. Pratt DS, Flavin DP, Kaplan MM. The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology 1996 Jan; 110: 271-4
152. 152. Yarze JC, Herlihy KJ, Fritz HP, et al. Azathioprine and 6-mercaptopurine and autoimmune hepatitis. Gastroenterology 1996 Jun; 110: 2027